The purpose of this study is to find out how quickly and to what extent BI 3000202 is processed in the body. The purpose of Part A is to find out how 3000202 moves through and exits the body of healthy people. The purpose of Part B is to find out how much BI 3000202 gets into the blood when participants take it as a tablet compared with when they get it as an infusion. Adults between 18 and 55 years of age can take part if the study doctor determines they are healthy. The doctors regularly check participants' health. To assess the study endpoints, the study staff takes blood, urine, and stool samples.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
16
BI 3000202 unlabelled
BI 3000202 \[14C\]-labelled
ICON-Groningen-62040
Groningen, Netherlands
RECRUITINGPart A: fe-urine, 0-tz (fraction excreted in urine as percentage of the administered dose over the time interval from 0 to the last quantifiable time point)
Time frame: up to 21 days
Part A: fe-faeces, 0-tz (fraction excreted in faeces as percentage of the administered dose over the time interval from 0 to the last quantifiable time point)
Time frame: up to 21 days
Part B: AUC0-∞ (area under the concentration-time curve of the analyte over the time interval from 0 extrapolated to infinity)
Time frame: up to 6 days
Part A: Cmax (maximum measured concentration of the analyte)
Time frame: up to 20 days
Part A: AUC0-tz (area under the concentration-time curve of the analyte over the time interval from 0 to the last quantifiable time point)
Time frame: up to 20 days
Part B: Cmax
Time frame: up to 6 days
Part B: AUC0-tz
Time frame: up to 6 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.